Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FLGT | US
-0.56
-2.42%
Healthcare
Diagnostics & Research
30/06/2024
30/08/2024
22.56
23.10
23.10
22.16
Fulgent Genetics Inc. together with its subsidiaries provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services such as gastrointestinal pathology dermatopathology urologic pathology breast pathology neuropathology and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer cardiovascular genetics reproductive health and neurodegenerative genetics as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile or PK profile of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes data suppression and comparison algorithms adaptive learning software and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance hospitals medical institutions other laboratories governmental bodies payors municipalities and large corporations and patients. The company was formerly known as Fulgent Diagnostics Inc. and changed its name to Fulgent Genetics Inc. in August 2016. Fulgent Genetics Inc. was founded in 2011 and is headquartered in Temple City California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
28.9%1 month
43.4%3 months
40.3%6 months
34.3%-
7.94
0.60
0.01
0.01
-4.34
1.32
1.32
-43.01M
683.49M
683.49M
-
-26.62
-98.60
4.70
-14.28
3.00
4.15
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.83
Range1M
3.91
Range3M
6.20
Rel. volume
0.82
Price X volume
3.05M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Celcuity Inc | CELC | Diagnostics & Research | 15.96 | 590.98M | -0.93% | n/a | 54.62% |
Surmodics Inc | SRDX | Diagnostics & Research | 39.63 | 565.40M | -0.10% | n/a | 28.32% |
National Research Corporation | NRC | Diagnostics & Research | 22.8 | 544.27M | 2.33% | 19.16 | 105.03% |
Varex Imaging Corporation | VREX | Diagnostics & Research | 12.48 | 509.95M | 1.63% | 16.86 | 80.92% |
Pacific Biosciences of California Inc | PACB | Diagnostics & Research | 1.37 | 373.36M | 0.74% | n/a | 187.73% |
Personalis Inc | PSNL | Diagnostics & Research | 5.44 | 358.58M | -6.21% | n/a | 41.56% |
Delcath Systems Inc | DCTH | Diagnostics & Research | 11 | 307.99M | 2.14% | n/a | 133.18% |
Biodesix Inc | BDSX | Diagnostics & Research | 1.96 | 284.55M | 5.95% | n/a | 169.94% |
Sera Prognostics Inc. | SERA | Diagnostics & Research | 7.35 | 245.26M | 5.15% | n/a | 2.27% |
Common Stock | PROF | Diagnostics & Research | 9.15 | 231.00M | -2.03% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 36.37 | 743.39M | 4.66% | n/a | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.25 | 722.36M | 0.32% | 56.82 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.94 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
The Marcus Corporation | MCS | Media - Diversified | 14.15 | 455.26M | 0.35% | n/a | 83.32% |
AMC Networks Inc | AMCX | Media - Diversified | 9.85 | 434.37M | -5.20% | 7.58 | 236.34% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 49.80 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.70 | 0.00% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 28.64 | 316.93M | -0.52% | 18.84 | -621.78% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.34 | 12.26 | Cheaper |
Ent. to Revenue | 1.32 | 41.25 | Cheaper |
PE Ratio | - | 39.64 | - |
Price to Book | 0.60 | 74.32 | Cheaper |
Dividend Yield | - | 1.12 | - |
Std. Deviation (3M) | 40.34 | 63.86 | Lower Risk |
Debt to Equity | 0.01 | 0.32 | Cheaper |
Debt to Assets | 0.01 | 0.34 | Cheaper |
Market Cap | 683.49M | 13.31B | Emerging |